Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.ENSC · Entity 8108 | Chief Financial Officer | February 17, 2022 | February 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date February 17, 2022 · Filed February 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2032-02-17 | Direct | 80,000 |
Reported balance
After 2022-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-17 · Grant · Acquired 80,000 · Balance 80,000 F1: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SENOMYX INC
Report date November 02, 2018 · Filed November 02, 2018
Section 16 reporting ended · disclosed 2018-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 1
1 source rowRow 1 · 2018-11-02 · Other · Disposed 432,810 · Balance 0 F1: Includes 46,173 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-02 · Disposition to issuer · Disposed 56,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-02 · Disposition to issuer · Disposed 21,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2028-03-14 | Direct | 0 |
Reported balance
After 2018-11-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-11-02 · Disposition to issuer · Disposed 90,800 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 46,173 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
F3: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 24, 2022 19:05 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 80,000 | Not disclosed Strike: $1.40 | Not disclosed |
DisclosureSEC source: 0001493152-22-005445 · ownership.xml · derivative · entry 1 Humphrey David Carl · CIK 0001708720 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-17 F1 · security: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · price: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · derivative.exercise_date: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. Read SEC document |
| February 04, 2022 Filed Feb 4, 2022 15:15 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 275,000 | Not disclosed Strike: $3.13 | Not disclosed |
DisclosureSEC source: 0001493152-22-003204 · ownership.xml · derivative · entry 1 Humphrey David Carl · CIK 0001708720 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2032-02-04 F1 · security: On February 4, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · price: On February 4, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · derivative.exercise_date: On February 4, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 19:15 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-016123 · ownership.xml · nonDerivative · entry 1 Humphrey David Carl · CIK 0001708720 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger, dated January 31, 2021, among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Upon completion of the Merger, the Reporting Person received a grant of 50,000 restricted stock units, which, subject generally to the Reporting Person's continued employment through each such date would vest as to 20,000 restricted stock units on December 15, 2021, an additional 15,000 restricted stock units on December 15, 2022, and an additional 15,000 restricted stock units on December 15, 2023. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:06 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 90,800 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-18-056995 · doc4.xml · derivative · entry 4 Humphrey David Carl · CIK 0001708720 · V.P. & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,800 shares Expires 2028-03-14 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:06 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 21,000 | Not disclosed Strike: $1.02 | Not disclosed |
DisclosureSEC source: 0001209191-18-056995 · doc4.xml · derivative · entry 3 Humphrey David Carl · CIK 0001708720 · V.P. & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires 2027-03-14 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:06 UTC | SENOMYX INC SNMX · Entity 162645 | Disposition to issuerStock Option (right to buy) · Derivative | 56,000 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-18-056995 · doc4.xml · derivative · entry 2 Humphrey David Carl · CIK 0001708720 · V.P. & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,000 shares Expires 2027-06-14 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 18:06 UTC | SENOMYX INC SNMX · Entity 162645 | OtherCommon Stock | 432,810 | $1.50 | $649,215.00 |
DisclosureSEC source: 0001209191-18-056995 · doc4.xml · nonDerivative · entry 1 Humphrey David Carl · CIK 0001708720 · V.P. & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 46,173 shares of Common Stock that were acquired by the Reporting Person on 8/31/18 pursuant to the Issuer's Employee Stock Purchase Plan. F2 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation ("Parent"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). Read SEC document |
| March 15, 2018 Filed Mar 21, 2018 18:52 UTC | SENOMYX INC SNMX · Entity 162645 | GrantStock option (right to buy) · Derivative | 90,800 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001437749-18-005185 · rdgdoc.xml · derivative · entry 2 Humphrey David Carl · CIK 0001708720 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,800 Underlying: Common Stock · 90,800 shares Expires 2028-03-14 F2 · derivative.exercise_date: The stock option was granted on 03/15/2018. The option vests over four years with 1/4 of the total number of shares subject to the option vesting on the first anniversary of the date of grant and 1/48th of the total number of shares subject to the option vesting monthly thereafter, until fully vested on 03/15/2022. Read SEC document |
| February 28, 2018 Filed Mar 21, 2018 18:52 UTC | SENOMYX INC SNMX · Entity 162645 | GrantCommon Stock | 36,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-005185 · rdgdoc.xml · nonDerivative · entry 1 Humphrey David Carl · CIK 0001708720 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,637 F1 · price: Although not required, the Reporting Person has elected to report 36,457 shares of Common Stock that were acquired by the Reporting Person on 2/28/18 pursuant to the Issuer's Employee Stock Purchase Plan F3 · balance_after: Includes 85,765 shares held by spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.